tradingkey.logo
tradingkey.logo
Search

Evaxion Biotech A/S

EVAX
Add to Watchlist
2.820USD
+0.030+1.07%
Close 07-31 16:00ETQuotes delayed by 15 min
23.52MMarket Cap
LossP/E TTM

EVAX Income Statement

You can find the annual or quarterly income statement of Evaxion Biotech A/S here for insights into the performance and operational efficiency of Evaxion Biotech A/S.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q1
FY2019Q4
Total revenue
--0.00
-100.00%0.00
148.33%7.49M
-75.97%37.00K
-100.00%0.00
67.12%122.00K
--3.02M
--154.00K
--51.00K
--73.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Revenue
--0.00
-100.00%0.00
148.33%7.49M
-75.97%37.00K
-100.00%0.00
67.12%122.00K
--3.02M
--154.00K
--51.00K
--73.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating expenses
-1.27%3.82M
-2.27%4.05M
-5.86%4.47M
-7.56%4.38M
-13.02%3.87M
-6.56%4.15M
-17.60%4.75M
-16.59%4.74M
-30.45%4.45M
-32.00%4.44M
-5.28%5.76M
-9.30%5.68M
-0.08%6.39M
-15.49%6.53M
2.89%6.08M
-10.92%6.26M
23.65%6.40M
66.22%7.72M
--5.91M
--7.03M
57.25%5.17M
24.76%4.64M
--3.29M
--3.72M
R&D expenses
6.59%2.30M
13.53%2.56M
18.29%3.09M
-21.33%2.17M
-23.98%2.16M
-1.87%2.25M
-7.63%2.61M
-6.27%2.75M
-26.38%2.84M
-43.58%2.30M
-30.43%2.83M
-28.60%2.94M
-19.82%3.85M
-33.82%4.07M
-7.90%4.07M
-19.55%4.11M
23.40%4.80M
115.63%6.15M
--4.42M
--5.11M
55.10%3.89M
-3.12%2.85M
--2.51M
--2.95M
Depreciation, depletion, and amortization
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-6.67%28.00K
----
--30.00K
Other operating expenses
----
----
--1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating profit
1.27%-3.82M
-0.70%-4.05M
274.58%3.02M
5.26%-4.34M
12.01%-3.87M
7.79%-4.02M
69.96%-1.73M
19.31%-4.58M
31.25%-4.40M
33.12%-4.36M
5.28%-5.76M
9.30%-5.68M
0.08%-6.39M
15.49%-6.53M
-2.89%-6.08M
10.92%-6.26M
-23.65%-6.40M
-66.22%-7.72M
---5.91M
---7.03M
-57.25%-5.17M
-24.76%-4.64M
---3.29M
---3.72M
Net non-operating interest income (expenses)
Non-operating interest income
-87.77%305.00K
----
3102.38%2.69M
-26.83%30.00K
-55.62%2.49M
3.40%578.00K
16.67%84.00K
-12.77%41.00K
1871.23%5.62M
698.57%559.00K
-89.76%72.00K
-96.95%47.00K
-45.09%285.00K
-90.62%70.00K
144.10%703.00K
4563.64%1.54M
-46.60%519.00K
702.15%746.00K
--288.00K
--33.00K
5975.00%972.00K
--93.00K
--16.00K
----
Non-operating interest expense
-16.37%332.00K
924.02%4.69M
254.17%1.36M
7.11%241.00K
61.38%397.00K
-48.83%458.00K
110.99%384.00K
12.50%225.00K
-24.54%246.00K
51.69%895.00K
-65.98%182.00K
-11.11%200.00K
106.33%326.00K
719.44%590.00K
949.02%535.00K
-54.55%225.00K
-46.80%158.00K
-66.36%72.00K
--51.00K
--495.00K
7325.00%297.00K
494.44%214.00K
--4.00K
--36.00K
Gains from sale of securities
----
---1.11M
----
-686.36%-129.00K
----
----
----
128.21%22.00K
----
----
----
---78.00K
----
----
----
----
----
----
----
----
----
----
----
---19.00K
Special income (expenses)
----
--2.57M
----
79.08%-346.00K
----
----
----
---1.65M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
--1.00K
--1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income before tax
-116.99%-3.85M
-58.12%-6.17M
314.28%4.35M
21.43%-5.03M
-281.56%-1.77M
16.94%-3.90M
65.41%-2.03M
-8.28%-6.40M
115.17%976.00K
33.29%-4.70M
0.73%-5.87M
-19.47%-5.91M
-6.58%-6.43M
0.03%-7.04M
-4.23%-5.92M
33.96%-4.95M
-34.18%-6.04M
-47.86%-7.05M
---5.67M
---7.49M
-37.24%-4.50M
-26.15%-4.77M
---3.28M
---3.78M
Income tax
-12.50%-216.00K
6.91%-256.00K
-176.04%-265.00K
2.01%-195.00K
11.93%-192.00K
-55.37%-275.00K
50.52%-96.00K
11.56%-199.00K
-12.37%-218.00K
-2.31%-177.00K
-10.86%-194.00K
-27.12%-225.00K
21.46%-194.00K
-113.08%-173.00K
58.82%-175.00K
73.54%-177.00K
39.31%-247.00K
363.55%1.32M
---425.00K
---669.00K
-126.11%-407.00K
-93.82%-502.00K
---180.00K
---259.00K
Income after tax
-129.68%-3.63M
-63.05%-5.92M
338.60%4.62M
22.06%-4.83M
-232.33%-1.58M
19.77%-3.63M
65.92%-1.94M
-9.06%-6.20M
119.13%1.19M
34.18%-4.52M
1.08%-5.68M
-19.19%-5.68M
-7.77%-6.24M
17.90%-6.87M
-9.33%-5.74M
30.08%-4.77M
-41.49%-5.79M
-96.29%-8.37M
---5.25M
---6.82M
-32.07%-4.09M
-21.17%-4.26M
---3.10M
---3.52M
Net income from continuous operations
-129.68%-3.63M
-63.08%-5.92M
338.66%4.62M
22.06%-4.83M
-232.33%-1.58M
19.77%-3.63M
65.92%-1.94M
-9.06%-6.20M
119.13%1.19M
34.18%-4.52M
1.08%-5.68M
-19.19%-5.68M
-7.77%-6.24M
17.90%-6.87M
-9.33%-5.74M
30.08%-4.77M
-41.49%-5.79M
-96.29%-8.37M
---5.25M
---6.82M
-32.07%-4.09M
-21.17%-4.26M
---3.10M
---3.52M
Other net gains and losses
----
---1.00K
--1.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
-129.68%-3.63M
-63.08%-5.92M
338.66%4.62M
22.06%-4.83M
-232.33%-1.58M
19.77%-3.63M
65.92%-1.94M
-9.06%-6.20M
119.13%1.19M
34.18%-4.52M
1.08%-5.68M
-19.19%-5.68M
-7.77%-6.24M
17.90%-6.87M
-9.33%-5.74M
30.08%-4.77M
-41.49%-5.79M
-96.29%-8.37M
---5.25M
---6.82M
-32.07%-4.09M
-21.17%-4.26M
---3.10M
---3.52M
Net income attributable to common shareholders
-129.68%-3.63M
-63.08%-5.92M
338.66%4.62M
22.06%-4.83M
-232.33%-1.58M
19.77%-3.63M
65.92%-1.94M
-9.06%-6.20M
119.13%1.19M
34.18%-4.52M
1.08%-5.68M
-19.19%-5.68M
-7.77%-6.24M
17.90%-6.87M
-9.33%-5.74M
30.08%-4.77M
-41.49%-5.79M
-96.29%-8.37M
---5.25M
---6.82M
-32.07%-4.09M
-21.17%-4.26M
---3.10M
---3.52M
Basic earnings per share
69.57%-0.01
95.34%-0.01
141.46%0.01
86.72%-0.02
-211.68%-0.03
80.18%-0.31
98.29%-0.04
94.51%-0.12
101.06%0.03
45.34%-1.56
14.76%-2.05
-5.00%-2.10
3.18%-2.42
85.77%-2.85
82.16%-2.41
88.89%-2.00
78.26%-2.50
-77.75%-20.00
---13.50
---18.00
-42.49%-11.50
-22.77%-11.25
---8.07
---9.16
Diluted earnings per share
69.57%-0.01
95.34%-0.01
141.46%0.01
86.72%-0.02
-211.68%-0.03
80.18%-0.31
98.29%-0.04
94.51%-0.12
101.06%0.03
45.34%-1.56
14.76%-2.05
-5.00%-2.10
3.18%-2.42
85.77%-2.85
82.16%-2.41
88.89%-2.00
78.26%-2.50
-77.75%-20.00
---13.50
---18.00
-42.49%-11.50
-22.77%-11.25
---8.07
---9.16
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Evaxion Biotech A/S's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing EVAX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Evaxion Biotech A/S's revenue at year end?

Evaxion Biotech A/S reported 7.53M in revenue for fiscal year 2025, up from 3.34M in the previous year.

What was Evaxion Biotech A/S's net income for the year?

Evaxion Biotech A/S posted -7.71M in net income for fiscal year 2025.

How much net income did Evaxion Biotech A/S post in the last quarter?

Evaxion Biotech A/S reported -3.63M in net income for the latest quarter。

What was Evaxion Biotech A/S's annual operating profit?

Evaxion Biotech A/S's operating income was -9.23M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.